



Anemia and CKD

Ιωάννης Γ. Γριβέας, MD, PhD

Ορισμός αναιμίας



- Αναιμία είναι η κατάσταση κατά την οποία ανευρίσκεται ελάττωση της αιμοσφαιρίνης, του αιματοκρίτη, ή και του αριθμού των ερυθρών, στη μονάδα του όγκου του αίματος, κάτω από τα φυσιολογικά όρια, για το φύλο και την ηλικία του ατόμου



Κριτήρια αναιμίας



- Οι "φυσιολογικές τιμές" εξαρτώνται από :
 - Το φύλο
 - Την ηλικία
 - Την γεωγραφική περιοχή



Αναιμία (Επίπεδα Hb)



Ηλικία ή φύλο	Hb (g/dl)	Hb (mmol/l)	Hct
Παιδιά (5 μηνών – 5 ετών)	< 11	< 6.83	33%
Παιδιά (5-12 ετών)	< 11,5	< 7.14	34%
Παιδιά (12-15 ετών)	< 12	< 7.45	36%
Μη-έγκυες γυναίκες (>15 ετών)	< 12	< 7.45	36%
Έγκυες γυναίκες	< 11	< 6.83	33%
Άνδρες (>15 ετών)	< 13	< 8.07	39%

World Health Organization. Worldwide prevalence of anaemia 1993-2005:

WHO global database on anaemia 2008. Available at

http://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency



WHO Classification of Anaemia



Πίνακας I.

Κατάταξη της αναιμίας ανάλογα με τη βαρύτητά της.


Σοβαρότης	WHO (g/dl)	NCI (g/dl)
Βαθμός 0 (φυσιολ.)	≥ 11	Φυσιολογική
Βαθμός 1 (ηπία)	9,5-10,9	10,0-φυσιολογική
Βαθμός 2 (μετρία)	8,0-9,4	8,0-10,0
Βαθμός 4 (σοβαρά)	6,5-7,9	6,5-7,9
Βαθμός 5 (απειλητική)	< 6,5	< 6,5



Αναιμία και Σιδηροπενική Αναιμία (ΣΑ)

Worldwide prevalence of anaemia 1993–2005

WHO Global Database
on Anaemia



- Η αναιμία παγκοσμίως συναντάται στο 24.8% του γενικού πληθυσμού, ενώ η σιδηροπενία αποτελεί το βασικότερο αίτιο



World Health Organization



Centers for Disease
Control and Prevention
Atlanta





Ο επιπλασμός της Αναιμίας WHO(1993-2005)



Table 3.2 Global anaemia prevalence and number of individuals affected

Population group	Prevalence of anaemia		Population affected	
	Percent	95% CI	Number (million)	95% CI
Preschool-age children	47.4	45.7-49.1	293	283-303
School-age children	25.4	19.9-30.9	305	238-371
Pregnant women	41.8	39.9-43.8	56	54-59
Non-pregnant women	30.2	28.7-31.6	468	446-491
Men	12.7	8.6-16.9	260	175-345
Elderly	23.9	18.3-29.4	164	126-202
Total population	24.8	22.9-26.7	1620	1500-1740

World Health Organization. Worldwide prevalence of anaemia 1993-2005:
WHO global database on anaemia 2008. Available at
http://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency



Τι αναφέρουν τα στοιχεία για την Αναιμία στην Ευρώπη



Table 3.3 *Anaemia prevalence and number of individuals affected in preschool-age children, pregnant women, and non-pregnant women in each WHO region*


WHO region	Preschool-age children ^a		Pregnant women		Non-pregnant women	
	Prevalence (%)	# affected (millions)	Prevalence (%)	# affected (millions)	Prevalence (%)	# affected (millions)
Africa	67.6 (64.3-71.0) ^b	83.5 (79.4-87.6)	57.1 (52.8-61.3)	17.2 (15.9-18.5)	47.5 (43.4-51.6)	69.9 (63.9-75.9)
Americas	29.3 (26.8-31.9)	23.1 (21.1-25.1)	24.1 (17.3-30.8)	3.9 (2.8-5.0)	17.8 (12.9-22.7)	39.0 (28.3-49.7)
South-East Asia	65.5 (61.0-70.0)	115.3 (107.3-123.2)	48.2 (43.9-52.5)	18.1 (16.4-19.7)	45.7 (41.9-49.4)	182.0 (166.9-197.1)
Europe	21.7 (15.4-28.0)	11.1 (7.9-14.4)	25.1 (18.6-31.6)	2.6 (2.0-3.3)	19.0 (14.7-23.3)	40.8 (31.5-50.1)
Eastern Mediterranean	46.7 (42.2-51.2)	0.8 (0.4-1.1)	44.2 (38.2-50.3)	7.1 (6.1-8.0)	32.4 (29.2-35.6)	39.8 (35.8-43.8)
Western Pacific	23.1 (21.9-24.4)	27.4 (25.9-28.9)	30.7 (28.8-32.7)	7.6 (7.1-8.1)	21.5 (20.8-22.2)	97.0 (94.0-100.0)
Global	47.4 (45.7-49.1)	293.1 (282.8-303.5)	41.8 (39.9-43.8)	56.4 (53.8-59.1)	30.2 (28.7-31.6)	468.4 (446.2-490.6)

^a Population subgroups: Preschool-age children (0.00-4.99 yrs); Pregnant women (no age range defined); Non-pregnant women (15.00-49.99 yrs).

^b 95% Confidence Intervals.

Αναιμία: κλινικές εκδηλώσεις

- Καταβολή
- Ζάλη
- Κεφαλαλγία
- Διαταραχές του ύπνου
- Ψυχρά άκρα
- Ανορεξία
- Αδυναμία συγκέντρωσης
- Αίσθημα παλμών και δύσπνοια μετά από μικρή κόπωση
- Κατάθλιψη



Αναιμία: βασικά σημεία (1)




- Η Αναιμία αποτελεί σοβαρό ιατροκοινωνικό πρόβλημα
- Προσβάλλει περίπου το 25% του πληθυσμού σε παγκόσμιο επίπεδο
- Έχει άμεση σχέση με το βιοτικό επίπεδο του πληθυσμού
- Η συχνότητά της είναι αυξημένη στα ηλικιωμένα άτομα
- 25 – 35 % των παθολογικών εισαγωγών σε νοσοκομείο είναι δυνατόν να παρουσιάζει αναιμία
- Αποτελεί δυσμενή προγνωστικό παράγοντα όταν συνυπάρχει με άλλα νοσήματα

Αναιμία: βασικά σημεία (2)




- Η αναιμία στις πιο πολλές περιπτώσεις είναι σύμπτωμα υποκείμενης νόσου και η θεραπευτική παρέμβαση θα πρέπει να έχει ως στόχο την ανάταξη μεν της αναιμίας, αλλά συγχρόνως την αντιμετώπιση της υποκείμενης νόσου, που είναι ο αιτιολογικός παράγοντας
- Τα συμπτώματα ποικίλουν, καθώς εξαρτώνται από την αιτία της αναιμίας, τη σοβαρότητα της, το χρόνο έναρξης της, καθώς και τη δυνατότητα προσαρμογής του οργανισμού στα χαμηλά επίπεδα

Ο σίδηρος είναι καθοριστικός στη διαδικασία της ερυθροποίησης



Ο σίδηρος και η ερυθροποιητίνη παίζουν ζωτικό ρόλο στην παραγωγή των ερυθρών κυττάρων



Ορισμός της σιδηροπενίας: Δείκτες αποθήκευσης και αξιοποίησης του σιδήρου



Φερριτίνη ορού – Αποθήκες σιδήρου



Μετρούμενη παράμετρος	Πλεονεκτήματα	Περιορισμοί
<ul style="list-style-type: none">Αποθήκες σιδήρου¹  <p>Φερριτίνη</p>	<ul style="list-style-type: none">Ο πιο χρήσιμος δείκτης για την αξιολόγηση των αποθηκών σιδήρου²Στα υγιή άτομα, η φερριτίνη ορού σχετίζεται με τα αποθέματα σιδήρου στον οργανισμό²	<ul style="list-style-type: none">Τα φυσιολογικά ή αυξημένα επίπεδα φερριτίνης δεν αποκλείουν απόλυτη ή λειτουργική σιδηροπενία³Διαφορές ανάλογα με το φύλο (φυσιολογικά χαμηλότερη στις γυναίκες)¹Αντιδραστήριο οξείας φάσης¹Τα επίπεδα της φερριτίνης μπορεί να είναι αυξημένα σε άτομα με συνυπάρχοντα φλεγμονώδη νοσήματα, λοίμωξη, κακοήθεια ή ηπατική νόσο^{2,3}

1. Wish JB. Clin J Am Soc Nephrol 2006;1:S4–8

2. Crichton RR, et al. Iron therapy with special emphasis on intravenous administration (4th edition). UNI-MED Verlag AG, Bremen

3. Macdougall IC. Curr Opin Nephrol Hypertens 1994;3:620–5

Η φερριτίνη είναι μια σημαντική παράμετρος για την αξιολόγηση της σιδηροπενίας




Εργαστηριακή Παράμετρος	Τι μετράει	Πλεονεκτήματα	Περιορισμοί
Φερριτίνη 	Αποθήκες σιδήρου ²	<ul style="list-style-type: none"> Ο πιο χρήσιμος δείκτης για την αξιολόγηση των αποθηκών σιδήρου⁴ Τα χαμηλά επίπεδα είναι εξαιρετικά ειδικά για ύπαρξη σιδηροπενίας³ Στα υγιή άτομα σχετίζεται με τα αποθέματα σιδήρου στον οργανισμό⁴ Εύκολη και ευρέως διαθέσιμη μέτρηση, με μέτριο κόστος 	Αντραστήριο οξείας φάσης ² π.χ. μπορεί να αυξηθεί από συνυπάρχοντα φλεγμονώδη νοσήματα, λοίμωξη, κακοήθεια ή ηπατική νόσο ^{1,4} . Τα φυσιολογικά ή αυξημένα επίπεδα φερριτίνης δεν αποκλείουν λειτουργική σιδηροπενία ¹ . Διαφορές ανάλογα με το φύλο (φυσιολογικά χαμηλότερη στις γυναίκες) ²


1. Macdougall IC. *Curr Opin Nephrol Hypertens* 1994;3:620–5. 2. Wish JB. *Clin J Am Soc Nephrol* 2006;1:S4–8.

3. Kalantar-Zadeh K, et al. *Clin J Am Soc Nephrol* 2006;1:S9–S18. 4. Crichton RR, et al. UNI-MED Verlag AG, Bremen 2006

How the kidney works



Mechanism of Progressive CKD



Source: Rossert, JA, et al, JASN 14:S173-177, 2003



- **Anaemia** is a state in which the quality and/or quantity of circulating red blood cells are below normal; it is associated with progression of CKD.
- Hb levels fall as kidney function declines.
- Adverse effects associated with anaemia include:
 - tiredness
 - shortness of breath
 - lethargy
 - palpitations
 - increased sensitivity to the cold
 - reduced cognition and concentration.



Anemia in CKD

- Prevalence
 - Stages 1-2: <10%
 - Stage 3: 20-40%
 - Stage 4: 50-60%
 - Stage 5: >70%
- Mechanisms
 - EPO deficiency
 - Iron deficiency and mobilization disorders
 - Shortened RBC lifespan
 - Hyperparathyroidism
 - Vitamin deficiencies



Current Treatment Paradigm / Options for Anemia

- Transfusion
- Erythropoiesis stimulating agents (ESAs)
(epoetin alpha & beta, darbepoetin, methoxy polyethylene glycol epoetin beta)
- Iron
(iron sucrose, ferric gluconate, iron dextran, ferumoxytol, ferrous sulfate)

Endogenous Erythropoietin

- Endogenous erythropoietin production primarily kidney & liver
- Physiologic concentrations
 - 5 to 20 mU/ml
 - Diurnal variation with higher afternoon & lower night-time levels
- Tissue hypoxia is main stimulus for modulating production
 - Erythropoietin levels in various conditions
 - High altitude training 3-5 fold increase over baseline
 - Acute blood loss (0.5L) 2-4 fold increase over baseline
 - Aplastic Anemia 500-20,000 mU/ml
 - Polycythemia V 2-5 mU/ml


EPO-producing cells in the kidney



Physiology and Pharmacology of Erythropoietin


Wolfgang Jelkmann

Institute of Physiology, University of Lübeck, Germany




Transfusion Medicine
and Hemotherapy

Editorial office
www.karger.com/tmh
ISSN: 0340-620X
e-ISSN: 1423-0220
Volume 40 Number 4
July 2013
Copyright © 2013 by Karger
Medical Publishers, Inc., Philadelphia, PA, USA




Erythropoietin



Physiology and Pharmacology of Erythropoietin

Wolfgang Jelkmann

Institute of Physiology, University of Lübeck, Germany



Transfusion Medicine
and Hemotherapy

- Contents
- Instructions for Authors
- Author Guidelines
- Submission of Manuscripts
- Review Process
- Peer Review
- Ethics
- Conflict of Interest Statement
- Instructions for Contributors
- Submission of Manuscripts
- Review Process
- Peer Review
- Ethics
- Conflict of Interest Statement
- Instructions for Contributors



Recombinant EPO preparations



'Epoetin' is the international non-proprietary drug name (INN) for eucaryotic cell-derived rhEpo, whose amino acid sequence is identical with that of endogenous human Epo. Differences in the amino acid residues chain are indicated by a random prefix (e.g. 'darbepoetin'). The glycosylation pattern is indicated by a Greek letter (alfa, beta, etc.). Two brands of innovator CHO cell-derived rhEpo, namely epoetin alfa and epoetin beta, were launched as anti-anemic agents

Recombinant EPO preparations



about 25 years ago. Epoetin alfa has been marketed in the USA as Epogen® (Amgen) for the treatment of CKD patients on hemodialysis and as Procrit® (Johnson and Johnson) for other indications through an agreement with Amgen, and outside the USA mainly as Eprex® or Erypo® (Johnson and Johnson subsidiary Ortho Biotech), and Espo® (Kirin). Epoetin beta has been mainly marketed as NeoRecormon® (F. Hoffmann-La Roche) and Epogin® (Chugai/F. Hoffmann-La Roche). The originator epoetins alfa and beta are used for the same major indications (anemias associated with CKD or myelosuppressive chemotherapy treated cancer). In 2009, epoetin theta has been launched as another stand-alone CHO cell-derived rhEpo (Eporatio®, Ratiopharm; Biopoin®, CT Arzneimittel) in the European Union (EU). In some parts of the world, CKD patients have been treated with epoetin omega, which is expressed in EPO cDNA-transfected baby hamster kidney (BHK, from Syrian hamster) cells, but apparently this product is not widely used.

Recombinant EPO preparations



indications of the reference product, Eprex/Erypo. One of the biosimilars has received the INN epoetin alfa (Binocrit[®], Sandoz; Epoetin alfa Hexal[®], Hexal Biotech; Abseamed[®], Medice Arzneimittel Putter) and the other epoetin zeta (Silapo[®], Stada; Retacrit[®], Hospira). The several brand names are ac-

There are recombinant ESAs with prolonged survival in circulation ('biobetter'). First darbepoetin alfa (Aranesp[®]; Amgen) has come, a hyperglycosylated analog (37.1 kDa) of rhEpo, which contains two additional N-glycans in association with an exchange of five amino acids [7]. Compared with the terminal half-life of IV administered epoetin (6–9 h), the half-life of darbepoetin alfa is three- to fourfold longer (25 h), which allows for less frequent application [39]. Another biobetter is methoxy polyethylene glycol-epoetin beta (methoxy PEG-epoetin beta; Mircera[®], F. Hoffmann-LaRoche). The half-life of methoxy PEG-epoetin beta (60 kDa) amounts to 130–140 h on IV injection. The prolonged in vivo survival of darbepoetin alfa and methoxy PEG-epoetin beta is in part due to a reduced EpoR binding affinity. 1 µg of darbepoetin alfa or of methoxy PEG-epoetin beta peptide corresponds biophysically to 200 IU rhEpo peptide. Clinically, however, the long-acting products may allow for dose reductions below the predicted 1: 200 ratio [39].




ESA Use in Anemia of CKD

- Erythropoiesis stimulating agents are typically given in large, pulsatile doses
- The majority of dialysis patients receive less than 10,000 units per week
- A significant minority of patients receive very high doses > 25,000 units per week

Weekly IV epoetin dose prescribed (3 month average) categories

National sample



Values for each month reflect average weekly dose prescribed, in months treated during year three (previous 2 months restricted to 2,010-494,363 U/mo).

Family sample transitioning from DOPPS 4 to 5 in January 2002 (see "Study Sample and Methods").

Familysample transitioning from DOPPS 5 to 6 in May 02/03 (see "Study Sample and Methods").

Source: US-DOQIS Practice Monitor, April 2006; <http://www.usdoqis.org>

ESAs Pros and Cons

- Pros
 - Reproduces deficient native hormone
 - Effective in most patients
 - Well tolerated in most patients
 - >25 years experience
 - IV administration invisible to HD patients
- Cons
 - SC administration in non-HD patients
 - Long-term cardiovascular events
 - ESA resistance
 - Do not address iron mobilization disorders

	Normal HCT (Besarab et al 1998, NEJM)	CHOIR (Singh et al 2006, NEJM)	CREATE (Druke et al 2006, NEJM)
Πλήθος ασθενών	1.233	1.432	603
Στάδιο νόσου	XNN – 5 με καρδιολογικό νόσημα	XNN 3 – 4	XNN 3 – 4
Στόχος μελέτης	Ποιες είναι οι επιπτώσεις της φυσιολογικοποίησης των τιμών Hb σε ασθενείς με XNN και καρδιά	Ποιά είναι τα βέλτιστα επίπεδα Hb;	Αν θα υπάρξει βελτίωση της καρδιακής λειτουργίας με τη διόρθωση της αναιμίας
Στόχοι Hb			
Χαμηλό όριο	10 g/dl	11.3 g/dl	10.5 – 11.5 g/dl
Υψηλό όριο	14 g/dl	13.5 g/dl	13 – 15 g/dl
Follow up	30 μήνες	16 μήνες	35 μήνες
Αποτέλεσμα	Σε ασθενείς με XNN-5 και συμφορητική καρδιακή ανεπάρκεια ή ισχαιμικό επεισόδιο, η πλήρης διόρθωση της αναιμίας δεν συστήνεται	Ο υψηλός στόχος οδήγησε σε αύξηση των κινδύνων σε σχέση με τον χαμηλό, χωρίς βελτίωση της QoL	Η διόρθωση της αναιμίας δεν φαίνεται να διορθώνει τον κίνδυνο εμφάνισης καρδιαγγειακών συμβαμάτων

The NEW ENGLAND JOURNAL of MEDICINE

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

Marc A. Pfeffer, M.D., Ph.D.; Emmanuel A. Budmann, M.D., Ph.D.; Chao-Yin Chen, Ph.D.; Mark E. Cooper, M.D.; Dick de Zeeuw, M.D., Ph.D.; Kai-Uwe Eckardt, M.D.; Jan M. Feyzi, M.S.; Peter Ivanovich, M.D.; Reshma Kewalramani, M.D.; Andrew S. Levey, M.D.; Eldrin F. Lewis, M.D., M.P.H.; Janet B. McGill, M.D.; John J.V. McMurray, M.D.; Patrick Parfrey, M.D.; Hans-Henrik Parving, M.D.; Giuseppe Remuzzi, M.D.; Ajay K. Singh, M.D.; Scott D. Solomon, M.D.; and Robert Toto, M.D., for the TREAT Investigators*

ABSTRACT

BACKGROUND:

Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been adequately tested.

METHODS:

In this study involving 4038 patients with diabetes, chronic kidney disease, and anemia, we randomly assigned 2012 patients to darbepoetin alfa to achieve a hemoglobin level of approximately 13 g per deciliter and 2026 patients to placebo, with rescue darbepoetin alfa when the hemoglobin level was less than 9.0 g per deciliter. The primary end points were the composite outcomes of death or a cardiovascular event (nonfatal myocardial infarction, congestive heart failure, stroke, or hospitalization for myocardial ischemia) and of death or end-stage renal disease.

RESULTS:

Death or a cardiovascular event occurred in 632 patients assigned to darbepoetin alfa and 602 patients assigned to placebo (hazard ratio for darbepoetin alfa vs. placebo, 1.05; 95% confidence interval [CI], 0.94 to 1.17; $P=0.41$). Death or end-stage renal disease occurred in 652 patients assigned to darbepoetin alfa and 618 patients assigned to placebo (hazard ratio, 1.06; 95% CI, 0.95 to 1.19; $P=0.29$). Fatal or nonfatal stroke occurred in 101 patients assigned to darbepoetin alfa and 53 patients assigned to placebo (hazard ratio, 1.92; 95% CI, 1.38 to 2.68; $P<0.001$). Red-cell transfusions were administered to 297 patients assigned to darbepoetin alfa and 496 patients assigned to placebo ($P<0.001$). There was only a modest improvement in patient-reported fatigue in the darbepoetin alfa group as compared with the placebo group.

CONCLUSIONS:

The use of darbepoetin alfa in patients with diabetes, chronic kidney disease, and moderate anemia who were not undergoing dialysis did not reduce the risk of either of the two primary composite outcomes (either death or a cardiovascular event or death or a renal event) and was associated with an increased risk of stroke. For many persons involved in clinical decision making, this risk will outweigh the potential benefits. (ClinicalTrials.gov number, NCT00093015.)

The affiliations of the authors are listed in the Appendix. Address reprint requests to Dr. Pfeffer at the Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at mpfeffer@partners.org, both harvard.edu.

*The Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) committee and teams are listed in the Appendix, and investigations and individual sites are listed in the Supplementary Appendix, available with the full text of this article at NEJM.org.

This article (10.1056/NEJMoa0907845) was published on October 30, 2009, at NEJM.org.

N Engl J Med 2009;361:
Copyright © 2009 Massachusetts Medical Society.



Oδηγίες - Guidelines

ERBP Position Paper 2010

Haemoglobin target



NDT Advance Access published June 29, 2010

doi: 10.1038/ndtadv.2010.16



Nephrol Dial Transplant

The ERBP group also feels that it is reasonable to suggest that:

(i) In patients with type 2 diabetes not undergoing dialysis (and probably in diabetics at all CKD stages), more caution is needed when treating anaemia with ESA therapy. In diabetic patients with a history of stroke, a lower target is more sensible (10-12 g/dL), balancing the risk-benefit of treatment and the desired Hb target in the individual patient. It is also of paramount importance to involve the patient in the decision making, and seek their personal views after a discussion about the benefits/risks of treatment. On this respect, the patient's opinion should be carefully taken into consideration.

(ii) The risk-benefit of increased transfusions should also be considered carefully, especially for patients eligible for transplantation."

Editorial Review

Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) Study

François Locatelli¹, Pedro Aljama², Bernhard Canaud³, Alfons Covic⁴, Angel De Francisco⁵, Iain C. Macdougall⁶, Andrea Winkler⁷, Raymond Vibhakar⁸ and On behalf of the Aranesp Working Group of European Renal Best Practice (ERBP)

¹Department of Nephrology, Dialysis and Renal Transplant, "Serrone-Mazzoni" Hospital, Lucca, Italy, ²Department of Nephrology, University Hospital, Bellvitge, Badalona, Spain, ³Nephrology, Odysseus and Institute Guy de Chenu, Espeyron University Hospital, Montpellier, France, ⁴University "de T. Pueyo" and Hospital "C. L. Pujade" Inf, Valencia, Department of Nephrology, Hospital Universitario Sant Joan de Déu, Barcelona, Spain, ⁵Department of Renal Medicine, King's College Hospital, London, UK, ⁶Department of Nephrology, Radiodiagnosis and Nucleotide Diagnostics, Medical University of Warsaw, Warsaw, Poland and ⁷Nephrology Section, Department of Internal Medicine, University Hospital, Ghent, Belgium

Correspondence and offprint requests to: François Locatelli, E-mail: ndt@locatelli.com

Acknowledgements

The European Renal Best Practice (ERBP), which are owned by ERA-EDTA, are guidelines for clinical practice in areas in which evidence is lacking or weak, together with practical recommendations on recently published randomized controlled trials, observational studies and meta-analyses. In 2005, the Aranesp Working Group of ERBP published its first position paper about the haemoglobin target to aim for with erythropoiesis-stimulating agents (ESAs) and on haemodialysis patients treated by ESAs [1]. This second position paper of the group follows the participating trials Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) Study [2]. This meta-analysis involved 17 trials comparing ESAs versus no ESA treatment in 2018 patients with type 2 diabetes, chronic kidney disease not on dialysis, and anaemia who were randomized to compare the correction of anaemia (haemoglobin target of 13 g/dL) using darbepoetin alfa or placebo (with a haemoglobin target value of 9 g/dL).

Following the findings of the TREAT study, the Aranesp Working Group of ERBP maintains its view that "Hb values of 11-12 g/dL should be generally sought in the CKD patient to reduce cardiovascular events (11 g/dL and thus the scores of ESKD) to those in the general population should also be considered. More caution is suggested when treating anaemia with ESA therapy in patients with type 2 diabetes not undergoing dialysis (and probably in diabetics at all CKD stages). In those with inclusion and exclusion criteria with a preponderance of stroke, possible benefits should be weighed up against the increased risks of stroke recurrence, when dialysing while Hb level seems low".

These recommendations are not intended to represent a strict guideline as they are the result of a systematic review of the evidence.

Keywords: anaemia, dialysis, diabetes, erythropoiesis-stimulating agents, stroke

Introduction (aims and scope)

Some years ago, the nephrology community planned a single set of international guidelines under the aegis of Kidney Disease Improving Global Outcomes (KDIGO) [3]. Consequently, the ERA-EDTA agreed to issue also some very specific guidelines, given the fact that in which we are living an era of new, revised or withdrawn statements or recently published multidisciplinary guidelines issued by other Italian or previous European Best Practice Guidelines (EBPG) [4]. Following the publication of KDIGO guidelines about anaemia in 2006/2007 [1,4], the Aranesp Working Group of European Renal Best Practice (ERBP) published its first position statement [2] giving an opinion on the best target of haemoglobin (Hb) and erythropoietin substitution therapy that may be adopted by ERA-EDTA in 2010 [1].

The aim of this second position statement continues to give guidance on the interpretation of the results of the Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) Study [2], and its possible relevance to recommended treatments and Hb targets to be used when treating chronic kidney disease (CKD) patients with erythropoiesis-stimulating agents (ESA) therapy. With

Οδηγίες - Guidelines

ERBP Position Paper 2010



Continue...

NDT Advance Access published June 28, 2010

doi: 10.1038/ndtadv

Editorial Review

Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) Study

NDT
Nephrology Disease Management

Francesco Locardi¹, Paolo Ajani², Bernard Gamiel³, Alireza Davi⁴, Angel De Francisco⁵, Jim C. Miodownik⁶, Andrew Wenzel⁷, Raymond Verhaert⁸ and On behalf of the Anemia Working Group of European Renal Best Practice (ERBP)

¹Department of Nephrology, Diabetology and Endocrinology, "Azienda Ospedaliera" Hospital, Lucca, Italy; ²Department of Nephrology, University Hospital Zurich, Zurich, Switzerland; ³Department of Nephrology, Dialysis and Internal Medicine, Guy's Department of Experimental Urology, King's College Hospital, London, UK; ⁴Department of Nephrology, University Hospital, Innsbruck, Austria; ⁵Department of Renal Medicine, King's College Hospital, London, UK; ⁶Department of Nephrology, Radiobiology and Medical Physics, Medical University of Warsaw, Warsaw, Poland; and ⁷Nephrology Section, Department of Internal Medicine, University Hospitals Ghent, Ghent, Belgium

Correspondence and offprint requests to: Francesco Locardi, Email: f.loardi@ospedalidellucca.it

Dear recommendations are not intended to represent a new guideline as they are the result of a systematic review of the evidence.

Keywords anemia, chronic disease, dialysis, erythropoiesis-stimulating agents, Hb

Introduction (aim and scope)

These recommendations are not intended to represent a new guideline as they are the result of a systematic review of the evidence. The European Renal Best Practice (ERBP), which are issued by ERA-EDTA, are suggestions for clinical practice in areas in which evidence is emerging or incomplete. They will be updated annually, as new evidence, published guidelines and recommendations, or an existing guideline and recommendations, in 2009, the Anemia Working Group of ERBP published its first position statement about the haemoglobin target range for erythropoiesis-stimulating agents (ESAs) and on issues that were not covered by KDOQI in 2006-07. The second position paper of the group follows the publication of the Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) Study. This multicentre, placebo-controlled trial compared candesartan and renoprotective therapy with Qd ESA therapy in chronic haemodialysis patients. The study found that the risk of death was decreased in patients on chronic haemodialysis receiving a target Hb of 11 g/dL, using epoetin alfa or darbepoetin alfa with a haemoglobin range of 9-10 g/dL.

Following the findings of the TREAT study, the Anemia Working Group of ERBP concluded that the values of 11-12 g/dL should be generally sought in the CKD population without intensively monitoring Hb g/dL and that the values of 12 g/dL therapy to achieve the target haemoglobin should be considered. However, it is suggested that treatment should be initiated in patients with type 2 diabetes and undergoing dialysis and primarily in children at risk (CKD stage 5). In those with inclusion in heart disease with a previous history of stroke, possible benefit should be weighed up against an increased risk of stroke recurrence, when deciding what Hb level to aim for.

"(iii) In diabetic patients with ischaemic heart disease or with a previous history of stroke, possible benefits of reduced need for coronary revascularization procedures and transfusions should be weighed up against an increased risk of stroke recurrence, when deciding which Hb level to aim for, and use of the lowest possible doses of ESA appears reasonable.

(iv) In patients with CKD and a previous history of cancer, the risk of tumour recurrence and related death should be considered when deciding whether or not to start ESA treatment. Again, in these patients, the lowest possible doses of ESA should be used."

Οδηγίες - Guidelines

ERBP Position Paper 2010

"Treatment of renal anemia"



NDT Advance access published June 29, 2010

doi: 10.1038/ndtadv.2010.447



Editorial Review

Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) Study

François Lauten¹, Pedro Aljama², Bernard Cauvel³, Adilia Corra⁴, Angel De Pascual⁵,
Sergio C. Massaguer⁶, Andreu Vilaseca⁷, Eugenio Viñolas⁸ and On Behalf of the Anemia Working
Group of European Renal Best Practice (ERBP)

¹Department of Nephrology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; ²Department of Nephrology, Hospital Universitario Central de Asturias, Oviedo, Spain; ³Department of Nephrology, Hospital Universitario Virgen Macarena, Seville, Spain; ⁴Department of Internal Medicine, King's College Hospital, London, UK; ⁵Department of Nephrology, Endocrinology and Metabolic Diseases, Medical University of Gdansk, Gdansk, Poland; ⁶Nephrology Section, Department of Internal Medicine, University Hospital Göttingen, Germany

⁷Correspondence and offprint requests to: Francisco Lauten, Institut Universitari Germans Trias i Pujol, ctra. Sant Joan Despi, 119-129, 08904 Badalona, Spain.

These recommendations are not intended to represent a new guideline as they are the result of a systematic review of the evidence.

Received 18 January 2010; accepted 20 March 2010; first published online 20 April 2010.

Introduction (aims and scope)

These recommendations are the methodological commonly planned in a single set of international guidelines under the auspices of the European Renal Best Practice (ERBP) group [1]. This second position paper of the group follows the first one published in 2005 [2], giving its opinion on the treatment of anaemia in patients with chronic kidney disease (CKD) and on the use of erythropoiesis-stimulating agents (ESA) in CKD patients. The multi-centre, randomised trial compared epoetin alfa (recombinant human erythropoietin) with darbepoetin alfa (type 2a fibroblast growth factor) in patients with CKD and anaemia who were not receiving dialysis or erythropoiesis-stimulating agents. The primary outcome was the mean packed cell volume (mean corpuscular haemoglobin concentration) (MCHC) at 3 months (from baseline) (mean difference 1.6%). Following the findings of the TREAT study, the Anemia Working Group of ERBP maintains its view that the values of 11–12 g/dL should be generally sought in the CKD population of those with haemoglobin < 11 g/dL; and that the mean MCHC target to achieve the target haemoglobin level is 34.5%. Moreover, the ERBP group agreed, when reaching a mean Hb with ESA therapy in patients with type 2 diabetes not undergoing dialysis and possibly in dialysis in all CKD stages, to those with haemoglobin levels < 11 g/dL and with a previous history of stroke, pre-emptive therapy should be initiated at approximately 10 g/dL, and not at the usual mean target of 11–12 g/dL, provided that the patient has no other risk factors for stroke, such as atrial fibrillation, hypertension, smoking, and/or diabetes, and no history of stroke.

The aim of this second position statement on anaemia is to give guidance on the interpretation of the recently published Trial to Reduce Cardiovascular Events with Erythropoiesis Therapy (TREAT) [3], and to provide reference to recommended treatments and Hb targets, to be used when treating chronic kidney disease (CKD) patients with erythropoiesis-stimulating agents (ESA) therapy, while

(i) Iron administration is an important factor for the successful treatment with any kind of ESA, in order to use the lowest dose for reaching and maintaining the desired Hb target

(ii) ESA treatment should not be started in patients who are iron-deficient



(iii) Iron replacement should be used first in any CKD patient who is proven or likely to be iron-deficient, and only once the iron stores are replete should ESA therapy be initiated

(iv) In CKD patients, ESA treatment should be considered when Hb levels are consistently below 11 g/dL (possibly < 10 g/dL in patients with type 2 diabetes and with a history of strokes), and all other causes of anaemia have been excluded; the threshold for treatment should be decided according to patient characteristics and symptoms, and the desired Hb target"

© 2010 Blackwell Publishing Ltd, *Journal of Internal Medicine* 267: 2846–2850

All rights reserved

Inadequately low EPO as cause of renal anemia




Rh EPO

- effective in almost all patients
- overall safe
- with relatively few limitations:
 - biological: high costs, limited stability
 - parenteral dosing required
 - occasionally immunogenic → PRCA
 - efficacy limited by iron availability
 - risks when targeting normal Hb levels



- Rational for new therapies
 - Interest in market participation
- Stimulation of endogenous EPO

Hypoxia – EPO feedback cycle




Modified from Koury, MJ, Red blood cell production and kinetics, In Ross's Principles of Transfusion Medicine, 6th Ed. (2016), p. 90.

Conclusions


- HIF Activators are an interesting and physiologic alternative to current treatment options for anemia
- The available clinical data appear promising
- No obvious safety signal YET
- Pending phase III clinical trials will help determine whether HIF Activators will one day replace ESAs and iron—**STAY TUNED**

Cardiorenal anemia syndrome: a vicious circle of destruction



Anemia as a cause of heart failure

Role of EPO in Preventing Progressive CKD



Source: Rossert, JA, et al, JASN 14:S173-177, 2003

Epoetin and IV Iron for Anemia in Patients with CHF


Prospective uncontrolled intervention study

26 anemic patients (Hb 10-11.9g%) with severe CHF despite being treated with maximally tolerated medications for > 6 mo had their anemia corrected

Intervention: Epoetin SC and Iron sucrose IV (Venofer)

Goal: To raise the Hb to above 12g%



Early treatment of anemia is associated with slower CKD progression



Source: Gouva C, et al. *Kidney Int* 66:753-760, 2004 (*P < 0.001)

Kidney disease is an EPO deficiency state.

The anemia of kidney disease is largely due to insufficient EPO to maintain normal RBC production rates.



Erslev AJ, Erythropoietin. *New Engl J Med* 1991;324:1339-1344. Left panel originally published in Erslev AJ, Caro J, Miller O, Silver R. Plasma erythropoietin in health and disease. *Ann Clin Lab Sci* 1980;10:250-257, and right panel courtesy of Dr. A Besarab.

CKD Clinic: Anemia Management



- Based on KDOQI, 2006
- Maintain Hb values between 11-13 g/dl using ESA agents
- Begin testing at all stages of CKD

CKD Clinic: Anemia Management



- Monthly monitoring of Hgb in ESA treated patients
- ESA doses should be decreased, not necessarily held when a downward trend in Hb is needed

CKD Clinic: Anemia Management



- Iron testing every month at initiation of ESA treatment
- Iron testing every 3 months during stable ESA treatment
- Sufficient iron should be administered to maintain the following indices of Fe status
 - Serum ferritin > 100 ng/ml
 - TSAT > 20 %
 - Discontinue IV Fe if ferritin > 500 ng/ml

Questions?

